RxDoctor Payments Data

April Lopez, APRN

Family · McAllen, TXNPI 1881023422

Payments from drug & device makers

What this record shows

This record is dominated by other: $414,900 of the $416,782 with a category attached, or 99.5%. Convatec Inc. accounts for 92.6% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $386,152 and has fallen 99.7% since, to $984 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$416,782in general payments, 2019–2025

Across 90 payments — averaging $4630.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$386K
  • Triad Life Sciences Inc.$29K
  • Medtronic$952
  • Organogenesis Inc.$321
  • Imbed Biosciences Inc.$198
  • AstraZeneca$197
  • plus $214 from 3 others

What the payments were for

  • Travel & lodging$7210%
  • Food & beverage$1,1610%
  • Other$414,900100%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Convatec Inc.49$386,100
Triad Life Sciences Inc.1$28,800
Medtronic14$952
Organogenesis Inc.4$321
Imbed Biosciences Inc.11$198
AstraZeneca8$197
Paratek Pharmaceuticals, Inc.1$124
Nuo Therapeutics1$69
Orthofix Medical, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$416,782 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$6,459,616
Medicare patients
52
Services billed
4,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol113$75,509
Bydureon BciseExenatide Microspheres34$53,656
SantylCollagenase Clostridium Hist.15$4,426
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,160
Ketoconazole36$906
Hydrocortisone19$631
Duloxetine Hcl16$606
Alendronate Sodium34$462
Atorvastatin Calcium42$435
Albuterol Sulfate HfaAlbuterol Sulfate15$345
Pantoprazole Sodium21$283
Levothyroxine Sodium29$274
Escitalopram Oxalate12$248
Mupirocin17$232
Metformin Hcl39$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$197$75,509113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →